The lawsuit was filed by Betty W., a woman from Alabama who was implanted with the C.R. Bard Eclipse® Vena Cava Filter on January 13, 2011.
Eclipse is one of the newest members of a long line of IVC filters that were linked to safety risks, pulled off the market without a recall, and replaced by “new” filters with nearly-identical designs and defects.
C.R. Bard began selling Eclipse as soon as it pulled the G2 off the market in 2010. That same year, a study linked the G2 with high rates of fracture and embolization. The fracture-risk was estimated at 38% within 5.5 years in a study published in 2014.
The G2 was introduced in 2005, the same year Bard pulled the Recovery off the market. Not surprisingly, Recovery was linked to a 40% 5.5-year fracture-risk in a study published in 2012.
Many people who were injured by the Eclipse say it never should have been allowed on the market. Or at the very least, Bard should have anticipated problems and studied it more thoroughly for safety risks.
The lawsuit was filed on November 18, 2016 in the U.S. District Court for the District of Arizona — Case No. 2:16-cv-04001.
As of mid-November, over 1,100 more IVC filter lawsuits were pending against C.R. Bard in Multi-District Litigation (MDL No. 2641)— In Re: Bard IVC Filters Products Liability Litigation.
The plaintiff is represented by Ben C. Martin of The Law Offices of Ben C. Martin in Dallas, Texas. He is on the plaintiffs’ steering committee of the Bard IVC Filter MDL.